Pfizer expects to apply this year for FDA approval of Aprela, a single-pill formulation of conjugated
estrogen and selective estrogen receptor modulator bazedoxifene.
Aprela can potentially ease menopausal symptoms and prevent osteoporosis, and it has a better tolerability and safety profile compared with
older hormone-replacement therapies, Pfizer executive Olivier Brandicourt said.

Related Summaries